Overview

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study was to assess the comparative safety and effectiveness of aztreonam for inhalation solution versus tobramycin inhalation solution in adult and pediatric patients with cystic fibrosis (CF) and pulmonary Pseudomonas aeruginosa (PA) infection.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Gilead Sciences
Collaborators:
Chiltern International Inc.
ClinPhone, Inc.
Covance
Treatments:
Anti-Bacterial Agents
Antibiotics, Antitubercular
Aztreonam
Pharmaceutical Solutions
Tobramycin
Criteria
Inclusion Criteria:

- Males or females aged 6 years and older

- Subjects with CF as diagnosed by one of the following: documented sweat chloride >= 60
mEq/L by quantitative pilocarpine iontophoresis test, or documented sweat sodium >= 60
mmol/L, or 2 well characterized genetic mutations in the Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR) gene, or abnormal nasal potential difference with
accompanying symptoms characteristic of CF

- Documented PA in an expectorated sputum or throat swab culture within 3 months prior
to Visit 1 or at Visit 1

- Subjects must be able to provide written informed consent/assent prior to any study
related procedures; parent/guardian must be able to give written informed consent as
necessary prior to any study related procedure

- Subjects must have received previous treatment with aerosolized antibiotics without
demonstration of drug intolerance

- FEV1 <= 75% predicted at Visit 1

- Ability to perform reproducible pulmonary function tests

- Chest radiograph at Visit 1 without significant acute findings (eg, infiltrates [lobar
or diffuse interstitial], pleural effusion, pneumothorax); or chest radiograph or
magnetic resonance image (MRI) obtained within the 180 days prior to Visit 1 without
acute findings and no significant intercurrent illness; chronic, stable findings (eg,
chronic scarring or atelectasis) are allowed

Exclusion Criteria:

- Current use of oral corticosteroids in doses exceeding the equivalent of 10 mg
prednisone a day or 20 mg prednisone every other day

- History of sputum or throat swab culture yielding B. cepacia in the previous 2 years

- Current requirement for daily continuous oxygen supplementation or requirement for
more than 2 L/minute at night

- Administration of any investigational drug or device within 28 days of Visit 1 or
within 6 half-lives of the investigational drug (whichever is longer)

- Known local or systemic hypersensitivity to monobactam antibiotics

- Known allergies/intolerance to tobramycin

- Inability to tolerate inhalation of a short acting beta agonist

- Changes in or initiation of chronic azithromycin treatment within 28 days prior to
Visit 1

- Administration of antipseudomonal antibiotics by inhalation, intravenous or oral
routes within the 14 days prior to Randomization/Visit 2

- Changes in antimicrobial, bronchodilator (BD), dornase alfa, or corticosteroid
medications within 7 days prior to Visit 1

- Changes in physiotherapy technique or schedule within 7 days prior to Visit 1

- History of lung transplantation

- Abnormal renal or hepatic function or serum chemistry at Visit 1, defined as aspartate
aminotransferase (AST), alanine aminotransferase (ALT) > 5 times upper limit of normal
range (ULN) or creatinine > 2 times ULN

- Positive pregnancy test at Visit 1; all women of childbearing potential will be tested

- Female of childbearing potential who is lactating or is not (in the opinion of the
investigator) practicing an acceptable method of birth control; female subjects who
utilize hormonal contraceptives as one of their birth control methods must have used
the same method for at least 3 months before study dosing

- Any serious or active medical or psychiatric illness, which in the opinion of the
investigator, would interfere with patient treatment, assessment, or compliance with
the protocol